Scienture Pharmaceuticals (NASDAQ: SNTX) Secures Third Patent for ARBLI™ Oral Suspension
Market Overview The U.S. market for losartan, a widely prescribed medication for hypertension, represents an annual revenue opportunity of approximately $241 million with around 72 million prescriptions filled each year. This sizable market demand underscores the potential for new product innovation to capture market share and extend patient treatment options. Scienture Pharmaceuticals (NASDAQ: SNTX) has positioned itself strongly within this landscape by offering ARBLI™, the first FDA-approved ready-to-use losartan potassium…
